Feeds:
Posts
Comments

Search Results for 'Heart Failure'


Studies Conducted at Harvard University on Heart Failure Recently Reported. Source: insurancenewsnet.com See on Scoop.it – Cardiovascular Disease: PHARMACO-THERAPY

Read Full Post »


Beta-blockers appeared to offer no or little clinical benefit to patients with heart failure and atrial fibrillation in a study presented at the European Society of Cardiology’s annual meeting and concurrently published online Sept. Source: linkis.com See on Scoop.it – Cardiovascular Disease: PHARMACO-THERAPY

Read Full Post »


Larry H Bernstein, MD, FCAP, Curator Leaders in Pharmaceutical Intelligence   Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction    RA. de Boer, DJ.A. Lok, T Jaarsma1, P van der Meer, AA. Voors, HL. Hillege & DJ. van Veldhuisen Annals of Medicine 2011; 43: 60–68. http://dx.doi.org:/10.3109/07853890.2010.538080 We studied 592 HFpatients who had been hospitalized for HFand were followed for 18 months. The primary end-point was a composite of all-cause mortality and HF hospitalization. A doubling of galectin-3 levels was associated with a hazard ratio (HR) of 1.97 (1.62–2.42) for the primary outcome (P = 0.001). After correction for age, gender, BNP, eGFR, and diabetes the HR was 1.38 (1.07– 1.78; P = 0.015). Galectin-3 levels were correlated with higher IL-6 and CRP levels (P = 0.002). Changes of galectin-3 levels after 6 months did not add prognostic information to the base-line value (n = 291); however, combining plasma galectin-3 and BNP levels increased prognostic value over either biomarker alone (ROC analysis, P = 0.05). The predictive value of galectin-3 was stronger in patients with preserved LVEF (n = 114) compared to patients with reduced LVEF (P = 0.001). Galectin-3 in Ambulatory Patients with Heart Failure: Results from the HF-ACTION Study GM Felker, M Fiuzat, LK. Shaw, R Clare, ,DJ. Whellan, et al. Circ Heart Fail. 2012 Jan; 5(1): 72–78. http://dx.doi.org:/10.1161/CIRCHEARTFAILURE.111.963637 Galectin-3 is a soluble ß-galactoside-binding lectin released by activated cardiac macrophages. Elevated levels of galectin-3 have been found to be associated with adverse outcomes in patients with heart failure. We evaluated the association between galectin-3 and long-term clinical outcomes in ambulatory heart failure patients enrolled in the HF-ACTION study. Galectin-3 is elevated in ambulatory heart failure patients and is associated with poor functional capacity and other known measures of heart failure severity. In univariate analysis, galectin-3 was significantly predictive of long-term outcomes, but this association did not persist after adjustment for other predictors, especially NTproBNP.  

Read Full Post »


Larry H Bernstein, MD, Curator Leaders in Pharmaceutical Intelligence   Natriuretic Peptides (BNP and Amino-terminal proBNP) Author: Larry Bernstein, M.D., (see Reviewers/Authors page) Revised: 12 December 2010, last major update December 2010 Copyright: (c) 2003-2010, PathologyOutlines.com, Inc. http://dx.doi.org:/PathologyOutlines.com/cardiac General ========================================================================= Brain natriuretic peptide (BNP), now known as B-type natriuretic peptide (also BNP), is a 32 amino acid polypeptide secreted by the cardiac ventricles in response to excessive stretching of cardiomyocytes (Wikipedia) BNP was originally identified in extracts of porcine brain, although in humans it is produced mainly in the cardiac ventricles BNP is co-secreted with a 76 amino acid N-terminal fragment (NT-proBNP), which is biologically inactive Indications ========================================================================= Evaluation of dyspneic patient with suspected congestive heart failure, regardless of renal function (J Am Coll Cardiol 2006;47:91) B-type natriuretic peptide levels are higher in patients with congestive heart failure than in dyspnea from other causes (J Am Coll Cardiol 2002;39:202, N Engl J Med 2004;350:647) NT-proBNP measurement is a valuable addition to standard clinical assessment for the identification and exclusion of acute CHF in the emergency department setting (Am J Cardiol 2005;95:9480) Clinical features ========================================================================= Reduces misdiagnosis of congestive heart failure, which occurs 50% to 75% of the time NT-proBNP is superior to BNP for predicting mortality and morbidity for heart failure (Clin Chem 2006;52:1528), and coexisting renal disease and heart failure (Clin Chem 2007;53:1511) Reference ranges ========================================================================= BNP levels below 100 pg/mL indicate no heart failure Limitations ========================================================================= Determination of endogenous BNP with the AxSYM assay using frozen plasma samples may not be valid after 1 day, but NT-proBNP as measured by the Elecsys assay may be stored at -20 degrees C for at least four months without a relevant loss of the immunoreactive analyte (Clin Chem Lab Med 2004;42:942) Additional references ========================================================================= Clin Chem 2007;53:1928, Am J Kidney Dis 2005;46:610, […]

Read Full Post »


An investigational heart failure drug being developed by Novartis cut deaths from heart disease by 20% compared with standard therapy, researchers reported today at the European Society of Cardiology. Source: http://www.medpagetoday.com See on Scoop.it – Cardiovascular Disease: PHARMACO-THERAPY

Read Full Post »


Drug Discovery & Development CardioCell Launches Phase 2a Chronic Heart Failure Trial Drug Discovery & Development CardioCell LLC, a Stemedica Cell Technologies Inc. Source: http://www.dddmag.com See on Scoop.it – Cardiovascular and vascular imaging

Read Full Post »


Variation in use of imaging tests in newly diagnosed heart failure Medical Xpress “Variations in testing were greatest for assessment of ischemia, in which testing guidelines are less certain.” One of the authors disclosed financial ties to a…

Read Full Post »


These lectures are presented for the education of healthcare professionals with a primary audience of pharmacy students. No recommendations are made and shou…

Read Full Post »


See on Scoop.it – Cardiovascular Disease: PHARMACO-THERAPY Stem cell therapy for heart failure treatment information. Stem Cell Institute uses stem cells from umbilical cord blood and Wharton’s jelly. Patient’s receive mutliple injections over the course of one week. See on http://www.cellmedicine.com

Read Full Post »


See on Scoop.it – Cardiovascular and vascular imaging Stem cell therapy for heart failure treatment information. Stem Cell Institute uses stem cells from umbilical cord blood and Wharton’s jelly. Patient’s receive mutliple injections over the course of one week. See on http://www.cellmedicine.com

Read Full Post »

« Prev - Next »